Comprehensive review of targeted therapy for colorectal cancer

Yuan-Hong Xie, Ying-Xuan Chen, Jing-Yuan Fang, Yuan-Hong Xie, Ying-Xuan Chen, Jing-Yuan Fang

Abstract

Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and chemotherapy have long been the first choices for cancer patients. However, the prognosis of CRC has never been satisfying, especially for patients with metastatic lesions. Targeted therapy is a new optional approach that has successfully prolonged overall survival for CRC patients. Following successes with the anti-EGFR (epidermal growth factor receptor) agent cetuximab and the anti-angiogenesis agent bevacizumab, new agents blocking different critical pathways as well as immune checkpoints are emerging at an unprecedented rate. Guidelines worldwide are currently updating the recommended targeted drugs on the basis of the increasing number of high-quality clinical trials. This review provides an overview of existing CRC-targeted agents and their underlying mechanisms, as well as a discussion of their limitations and future trends.

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1. United States of America Food…
Fig. 1. United States of America Food and Drug Administration (FDA)-approved targeted agents in colorectal cancer.
VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor; EGFR: epidermal growth factor receptor
Fig. 2. Pathways offering potential sites for…
Fig. 2. Pathways offering potential sites for targeted therapy.
CRC: colorectal cancer; VEGF/VEGFR: vascular endothelial growth factor/vascular endothelial growth factor receptor; EGF/EGFR: epidermal growth factor/epidermal growth factor receptor; HGF: hepatocyte growth factor; c-MET: mesenchymal–epithelial transition factor; IGF/IGF-1R: insulin-like growth factor/ insulin-like growth factor 1 receptor; TGF: transforming growth factor
Fig. 3. Overview of National Comprehensive Cancer…
Fig. 3. Overview of National Comprehensive Cancer Network (NCCN)-recommended targeted agents.
HGF: hepatocyte growth factor; c-MET: mesenchymal–epithelial transition factor; VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor; EGFR: epidermal growth factor receptor; EGF: epidermal growth factor; HER2: human epidermal growth factor 2; CTLA-4: cytotoxic T lymphocyte-associated antigen 4; PD-1: programmed death-1; PD-L1: programmed death ligand 1; PI3K: phosphoinositide 3-kinase; AKT: protein kinase B, also known as PKB; mTOR: mammalian target of rapamycin; MEK: mitogen-activated protein kinase; ERK: extracellular signal-regulated kinase. *These agents have not been recommended by the NCCN. **This agent has been approved by the National Medical Products Administration of China (NMPA), but not by the United States of America Food and Drug Administration (FDA)
Fig. 4. National Comprehensive Cancer Network (NCCN)-recommended…
Fig. 4. National Comprehensive Cancer Network (NCCN)-recommended strategy for metastatic colorectal cancer targeted therapy.
mCRC: metastatic colorectal cancer; EGFR: epidermal growth factor receptor; VEGF: vascular endothelial growth factor; PD-1/L1: programmed death-1/programmed death ligand 1; dMMR: deficient mismatch repair; pMMR: proficient mismatch repair; HER2: human epidermal growth factor 2; BSC: best supportive care; WT: wild type; mut: mutated; amp: amplified. *The NCCN recommends initial administration of PD-1/PD-L1 therapy only in patients in poor functional status
Fig. 5. Crosstalk and bypass mechanisms between…
Fig. 5. Crosstalk and bypass mechanisms between pathways.
VEGFR: vascular endothelial growth factor receptor; EGFR: epidermal growth factor receptor; c-MET: mesenchymal–epithelial transition factor; IGF-1R: insulin-like growth factor 1 receptor; TGF-β: transforming growth factor-β; RON-R: recepteur d’Origine nantais; PDGFR: platelet-derived growth factor receptor; *with multiple isoforms

References

    1. Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424.
    1. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394:1467–1480. doi: 10.1016/S0140-6736(19)32319-0.
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J. Clin. 2019;69:7–34. doi: 10.3322/caac.21551.
    1. Kuipers EJ, et al. Colorectal cancer. Nat. Rev. Dis. Prim. 2015;1:15065. doi: 10.1038/nrdp.2015.65.
    1. Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat. Rev. Gastroenterol. Hepatol. 2019;16:713–732. doi: 10.1038/s41575-019-0189-8.
    1. Sanchez-Gundin J, Fernandez-Carballido AM, Martinez-Valdivieso L, Barreda-Hernandez D, Torres-Suarez AI. New trends in the therapeutic approach to metastatic colorectal cancer. Int J. Med. Sci. 2018;15:659–665. doi: 10.7150/ijms.24453.
    1. Wolf AMD, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J. Clin. 2018;68:250–281. doi: 10.3322/caac.21457.
    1. van der Stok EP, Spaander MCW, Grunhagen DJ, Verhoef C, Kuipers EJ. Surveillance after curative treatment for colorectal cancer. Nat. Rev. Clin. Oncol. 2017;14:297–315. doi: 10.1038/nrclinonc.2016.199.
    1. Messersmith WA. NCCN guidelines updates: management of metastatic colorectal cancer. J. Natl Compr. Cancer Netw. 2019;17:599–601.
    1. Brown KGM, Solomon MJ, Mahon K, O’Shannassy S. Management of colorectal cancer. BMJ. 2019;366:l4561. doi: 10.1136/bmj.l4561.
    1. Labianca R, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013;24(Suppl. 6):vi64–vi72. doi: 10.1093/annonc/mdt354.
    1. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2014;25(Suppl. 3):iii1–iii9.
    1. Seymour MT, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007;370:143–152. doi: 10.1016/S0140-6736(07)61087-3.
    1. Koopman M, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet. 2007;370:135–142. doi: 10.1016/S0140-6736(07)61086-1.
    1. Colucci G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J. Clin. Oncol. 2005;23:4866–4875. doi: 10.1200/JCO.2005.07.113.
    1. Tournigand C, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 2004;22:229–237. doi: 10.1200/JCO.2004.05.113.
    1. Vera R, et al. Current controversies in the management of metastatic colorectal cancer. Cancer Chemother. Pharm. 2015;76:659–677. doi: 10.1007/s00280-015-2808-6.
    1. Falcone A, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol. 2007;25:1670–1676. doi: 10.1200/JCO.2006.09.0928.
    1. Souglakos J, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) Br. J. Cancer. 2006;94:798–805. doi: 10.1038/sj.bjc.6603011.
    1. Cassidy J, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J. Clin. Oncol. 2004;22:2084–2091. doi: 10.1200/JCO.2004.11.069.
    1. Goldberg RM, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 2004;22:23–30. doi: 10.1200/JCO.2004.09.046.
    1. Brodsky FM. Monoclonal antibodies as magic bullets. Pharm. Res. 1988;5:1–9. doi: 10.1023/A:1015860525341.
    1. Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. Eur. J. Pharm. 2018;834:188–196. doi: 10.1016/j.ejphar.2018.07.034.
    1. Oh DY, Bang YJ. HER2-targeted therapies—a role beyond breast cancer. Nat. Rev. Clin. Oncol. 2020;17:33–48. doi: 10.1038/s41571-019-0268-3.
    1. Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat. Rev. Drug Discov. 2018;17:353–377. doi: 10.1038/nrd.2018.21.
    1. Tariman JD. Changes in cancer treatment: Mabs, Mibs, Mids, Nabs, and Nibs. Nurs. Clin. N. Am. 2017;52:65–81. doi: 10.1016/j.cnur.2016.10.004.
    1. Tiwari A, Saraf S, Verma A, Panda PK, Jain SK. Novel targeting approaches and signaling pathways of colorectal cancer: An insight. World J. Gastroenterol. 2018;24:4428–4435. doi: 10.3748/wjg.v24.i39.4428.
    1. Krishnamurthy N, Kurzrock R. Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treat. Rev. 2018;62:50–60. doi: 10.1016/j.ctrv.2017.11.002.
    1. Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25:282–303. doi: 10.1016/j.ccr.2014.02.025.
    1. Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nat. Rev. Cancer. 2013;13:663–673. doi: 10.1038/nrc3559.
    1. Roskoski R., Jr. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharm. Res. 2019;139:395–411. doi: 10.1016/j.phrs.2018.11.014.
    1. Vecchione L, Jacobs B, Normanno N, Ciardiello F, Tejpar S. EGFR-targeted therapy. Exp. Cell Res. 2011;317:2765–2771. doi: 10.1016/j.yexcr.2011.08.021.
    1. Wang Z. ErbB receptors and cancer. Methods Mol. Biol. 2017;1652:3–35. doi: 10.1007/978-1-4939-7219-7_1.
    1. Hsu JL, Hung MC. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev. 2016;35:575–588. doi: 10.1007/s10555-016-9649-6.
    1. Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat. Rev. Cancer. 2017;17:637–658. doi: 10.1038/nrc.2017.84.
    1. Roskoski R., Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharm. Res. 2014;79:34–74. doi: 10.1016/j.phrs.2013.11.002.
    1. Hayes DF. HER2 and breast cancer—a phenomenal success story. N. Engl. J. Med. 2019;381:1284–1286. doi: 10.1056/NEJMcibr1909386.
    1. Boku N. HER2-positive gastric cancer. Gastric Cancer. 2014;17:1–12. doi: 10.1007/s10120-013-0252-z.
    1. Takegawa N, Yonesaka K. HER2 as an emerging oncotarget for colorectal cancer treatment after failure of anti-epidermal growth factor receptor therapy. Clin. Colorectal Cancer. 2017;16:247–251. doi: 10.1016/j.clcc.2017.03.001.
    1. Kiavue Nicolas, Cabel Luc, Melaabi Samia, Bataillon Guillaume, Callens Celine, Lerebours Florence, Pierga Jean-Yves, Bidard Francois-Clement. ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics. Oncogene. 2019;39(3):487–502. doi: 10.1038/s41388-019-1001-5.
    1. Veikkolainen V, et al. Function of ERBB4 is determined by alternative splicing. Cell Cycle. 2011;10:2647–2657. doi: 10.4161/cc.10.16.17194.
    1. Junttila TT, et al. Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res. 2005;65:1384–1393. doi: 10.1158/0008-5472.CAN-04-3150.
    1. Saintigny P, Burger JA. Recent advances in non-small cell lung cancer biology and clinical management. Discov. Med. 2012;13:287–297.
    1. Wang X, Goldstein D, Crowe PJ, Yang JL. Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence. OncoTargets Ther. 2016;9:5461–5473. doi: 10.2147/OTT.S94745.
    1. Bose R, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2013;3:224–237. doi: 10.1158/-12-0349.
    1. Ishibashi K, et al. Nuclear ErbB4 signaling through H3K9me3 is antagonized by EGFR-activated c-Src. J. Cell Sci. 2013;126:625–637. doi: 10.1242/jcs.116277.
    1. Pearson G, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 2001;22:153–183.
    1. Wu P, Wee P, Jiang J, Chen X, Wang Z. Differential regulation of transcription factors by location-specific EGF receptor signaling via a spatio-temporal interplay of ERK activation. PLoS ONE. 2012;7:e41354. doi: 10.1371/journal.pone.0041354.
    1. Kim EK, Choi EJ. Compromised MAPK signaling in human diseases: an update. Arch. Toxicol. 2015;89:867–882. doi: 10.1007/s00204-015-1472-2.
    1. Mizukami T, Izawa N, Nakajima TE, Sunakawa Y. Targeting EGFR and RAS/RAF signaling in the treatment of metastatic colorectal cancer: from current treatment strategies to future perspectives. Drugs. 2019;79:633–645. doi: 10.1007/s40265-019-01113-0.
    1. Davies H, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954. doi: 10.1038/nature00766.
    1. Samatar AA, Poulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat. Rev. Drug Discov. 2014;13:928–942. doi: 10.1038/nrd4281.
    1. Taieb J, Lapeyre-Prost A, Laurent Puig P, Zaanan A. Exploring the best treatment options for BRAF-mutant metastatic colon cancer. Br. J. Cancer. 2019;121:434–442. doi: 10.1038/s41416-019-0526-2.
    1. Ducreux M, et al. Molecular targeted therapy of BRAF-mutant colorectal cancer. Ther. Adv. Med. Oncol. 2019;11:1758835919856494. doi: 10.1177/1758835919856494.
    1. Okano J, Gaslightwala I, Birnbaum MJ, Rustgi AK, Nakagawa H. Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. J. Biol. Chem. 2000;275:30934–30942. doi: 10.1074/jbc.M004112200.
    1. Elmenier FM, Lasheen DS, Abouzid KAM. Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer. Eur. J. Med. Chem. 2019;183:111718. doi: 10.1016/j.ejmech.2019.111718.
    1. Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Semin. Cancer Biol. 2019;59:125–132. doi: 10.1016/j.semcancer.2019.07.009.
    1. Tang F, Wang Y, Hemmings BA, Ruegg C, Xue G. PKB/Akt-dependent regulation of inflammation in cancer. Semin. Cancer Biol. 2018;48:62–69. doi: 10.1016/j.semcancer.2017.04.018.
    1. Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017;169:381–405. doi: 10.1016/j.cell.2017.04.001.
    1. Weisheit S, Schafer C, Mertens C, Berndt A, Liebmann C. PKCepsilon acts as negative allosteric modulator of EGF receptor signalling. Cell Signal. 2011;23:436–448. doi: 10.1016/j.cellsig.2010.10.018.
    1. Koss H, Bunney TD, Behjati S, Katan M. Dysfunction of phospholipase Cgamma in immune disorders and cancer. Trends Biochem. Sci. 2014;39:603–611. doi: 10.1016/j.tibs.2014.09.004.
    1. Choi JH, et al. Phospholipase C-gamma1 is a guanine nucleotide exchange factor for dynamin-1 and enhances dynamin-1-dependent epidermal growth factor receptor endocytosis. J. Cell Sci. 2004;117:3785–3795. doi: 10.1242/jcs.01220.
    1. Wahl MI, Daniel TO, Carpenter G. Antiphosphotyrosine recovery of phospholipase C activity after EGF treatment of A-431 cells. Science. 1988;241:968–970. doi: 10.1126/science.2457254.
    1. Margolis B, et al. EGF induces tyrosine phosphorylation of phospholipase C-II: a potential mechanism for EGF receptor signaling. Cell. 1989;57:1101–1107. doi: 10.1016/0092-8674(89)90047-0.
    1. Meisenhelder J, Suh PG, Rhee SG, Hunter T. Phospholipase C-gamma is a substrate for the PDGF and EGF receptor protein-tyrosine kinases in vivo and in vitro. Cell. 1989;57:1109–1122. doi: 10.1016/0092-8674(89)90048-2.
    1. Anderson D, et al. Binding of SH2 domains of phospholipase C gamma 1, GAP, and Src to activated growth factor receptors. Science. 1990;250:979–982. doi: 10.1126/science.2173144.
    1. Margolis B, et al. Effect of phospholipase C-gamma overexpression on PDGF-induced second messengers and mitogenesis. Science. 1990;248:607–610. doi: 10.1126/science.2333512.
    1. Nappi A, et al. Metastatic colorectal cancer: role of target therapies and future perspectives. Curr. Cancer Drug Targets. 2018;18:421–429. doi: 10.2174/1568009617666170209095143.
    1. Dai L, et al. DAG/PKCdelta and IP3/Ca(2)(+)/CaMK IIbeta operate in parallel to each other in PLCgamma1-driven cell proliferation and migration of human gastric adenocarcinoma cells, through Akt/mTOR/S6 pathway. Int. J. Mol. Sci. 2015;16:28510–28522. doi: 10.3390/ijms161226116.
    1. Wang Y, Wu J, Wang Z. Akt binds to and phosphorylates phospholipase C-gamma1 in response to epidermal growth factor. Mol. Biol. Cell. 2006;17:2267–2277. doi: 10.1091/mbc.e05-10-0918.
    1. Ye K, et al. Phospholipase C gamma 1 is a physiological guanine nucleotide exchange factor for the nuclear GTPase PIKE. Nature. 2002;415:541–544. doi: 10.1038/415541a.
    1. Li S, Wang Q, Wang Y, Chen X, Wang Z. PLC-gamma1 and Rac1 coregulate EGF-induced cytoskeleton remodeling and cell migration. Mol. Endocrinol. 2009;23:901–913. doi: 10.1210/me.2008-0368.
    1. Geiger JL, Grandis JR, Bauman JE. The STAT3 pathway as a therapeutic target in head and neck cancer: barriers and innovations. Oral Oncol. 2016;56:84–92. doi: 10.1016/j.oraloncology.2015.11.022.
    1. Khanna P, Chua PJ, Bay BH, Baeg GH. The JAK/STAT signaling cascade in gastric carcinoma (Review) Int. J. Oncol. 2015;47:1617–1626. doi: 10.3892/ijo.2015.3160.
    1. Chen Z, et al. EGFR family and Src family kinase interactions: mechanics matters? Curr. Opin. Cell Biol. 2018;51:97–102. doi: 10.1016/j.ceb.2017.12.003.
    1. Egloff AM, Grandis JR. Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. Semin. Oncol. 2008;35:286–297. doi: 10.1053/j.seminoncol.2008.03.008.
    1. Mendelsohn J, Prewett M, Rockwell P, Goldstein NI. CCR 20th anniversary commentary: a chimeric antibody, C225, inhibits EGFR activation and tumor growth. Clin. Cancer Res. 2015;21:227–229. doi: 10.1158/1078-0432.CCR-14-2491.
    1. Cunningham D, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004;351:337–345. doi: 10.1056/NEJMoa033025.
    1. Jonker DJ, et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 2007;357:2040–2048. doi: 10.1056/NEJMoa071834.
    1. Van Cutsem E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 2009;360:1408–1417. doi: 10.1056/NEJMoa0805019.
    1. Tabernero J, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 2007;25:5225–5232. doi: 10.1200/JCO.2007.13.2183.
    1. Maughan TS, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011;377:2103–2114. doi: 10.1016/S0140-6736(11)60613-2.
    1. Tveit KM, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J. Clin. Oncol. 2012;30:1755–1762. doi: 10.1200/JCO.2011.38.0915.
    1. Van Cutsem E, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J. Clin. Oncol. 2015;33:692–700. doi: 10.1200/JCO.2014.59.4812.
    1. Aranda E, et al. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: phase II randomised MACRO2 TTD study. Eur. J. Cancer. 2018;101:263–272. doi: 10.1016/j.ejca.2018.06.024.
    1. Van Cutsem E, et al. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J. Clin. Oncol. 2012;30:2861–2868. doi: 10.1200/JCO.2011.40.9243.
    1. Yarom N, Jonker DJ. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. Discov. Med. 2011;11:95–105.
    1. Fakih M, Vincent M. Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr. Oncol. 2010;17(Suppl. 1):S18–S30.
    1. Douillard JY, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 2010;28:4697–4705. doi: 10.1200/JCO.2009.27.4860.
    1. Douillard JY, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann. Oncol. 2014;25:1346–1355. doi: 10.1093/annonc/mdu141.
    1. Modest DP, et al. Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials. Int. J. Cancer. 2019;145:576–585. doi: 10.1002/ijc.32110.
    1. Pietrantonio F, et al. First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study. J. Clin. Oncol. 2018;36:3505–3505. doi: 10.1200/JCO.2018.36.15_suppl.3505.
    1. Price TJ, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014;15:569–579. doi: 10.1016/S1470-2045(14)70118-4.
    1. Sobrero AF, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008;26:2311–2319. doi: 10.1200/JCO.2007.13.1193.
    1. Cohn AL, et al. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Clin. Colorectal Cancer. 2011;10:171–177. doi: 10.1016/j.clcc.2011.03.022.
    1. Seymour MT, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol. 2013;14:749–759. doi: 10.1016/S1470-2045(13)70163-3.
    1. Van Cutsem E, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 2007;25:1658–1664. doi: 10.1200/JCO.2006.08.1620.
    1. Qin S, et al. Efficacy and tolerability of first-line cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX-4) versus FOLFOX-4 in patients with RAS wild-type metastatic colorectal cancer: the Open-Label, Randomized, Phase III TAILOR Trial. J. Clin. Oncol. 2018;36:3031–3039. doi: 10.1200/JCO.2018.78.3183.
    1. Missiaglia E, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann. Oncol. 2014;25:1995–2001. doi: 10.1093/annonc/mdu275.
    1. Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. Eur. J. Cancer. 2017;70:87–98. doi: 10.1016/j.ejca.2016.10.007.
    1. Creasy JM, et al. The impact of primary tumor location on long-term survival in patients undergoing hepatic resection for metastatic colon cancer. Ann. Surg. Oncol. 2018;25:431–438. doi: 10.1245/s10434-017-6264-x.
    1. Van Cutsem E, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 2016;27:1386–1422. doi: 10.1093/annonc/mdw235.
    1. Lito P, et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell. 2012;22:668–682. doi: 10.1016/j.ccr.2012.10.009.
    1. Corcoran RB, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012;2:227–235. doi: 10.1158/-11-0341.
    1. Corcoran R.B., André T., Yoshino T., Bendell J.C., Atreya C.E., Schellens J.H.M., Ducreux M.P., McRee A., Siena S., Middleton G., Gordon M., Humblet Y., Muro K., Elez E., Yaeger R., Sidhu R., Squires M., Jaeger S., Rangwala F., Van Cutsem E. Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC) Annals of Oncology. 2016;27:vi150. doi: 10.1093/annonc/mdw370.04.
    1. Prahallad A, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483:100–103. doi: 10.1038/nature10868.
    1. Yang H, et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res. 2012;72:779–789. doi: 10.1158/0008-5472.CAN-11-2941.
    1. van Geel R, et al. A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer. Cancer Discov. 2017;7:610–619. doi: 10.1158/-16-0795.
    1. Corcoran RB, et al. Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer. Cancer Discov. 2018;8:428–443. doi: 10.1158/-17-1226.
    1. Hong DS, et al. Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discov. 2016;6:1352–1365. doi: 10.1158/-16-0050.
    1. Kopetz S, et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406) J. Clin. Oncol. 2017;35:520–520. doi: 10.1200/JCO.2017.35.4_suppl.520.
    1. Tabernero J, et al. Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC) J. Clin. Oncol. 2016;34:3544–3544. doi: 10.1200/JCO.2016.34.15_suppl.3544.
    1. Kopetz Scott, Grothey Axel, Yaeger Rona, Van Cutsem Eric, Desai Jayesh, Yoshino Takayuki, Wasan Harpreet, Ciardiello Fortunato, Loupakis Fotios, Hong Yong Sang, Steeghs Neeltje, Guren Tormod K., Arkenau Hendrik-Tobias, Garcia-Alfonso Pilar, Pfeiffer Per, Orlov Sergey, Lonardi Sara, Elez Elena, Kim Tae-Won, Schellens Jan H.M., Guo Christina, Krishnan Asha, Dekervel Jeroen, Morris Van, Calvo Ferrandiz Aitana, Tarpgaard L.S., Braun Michael, Gollerkeri Ashwin, Keir Christopher, Maharry Kati, Pickard Michael, Christy-Bittel Janna, Anderson Lisa, Sandor Victor, Tabernero Josep. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer. New England Journal of Medicine. 2019;381(17):1632–1643. doi: 10.1056/NEJMoa1908075.
    1. H B, M K, CP P. Colorectal cancer. Lancet. 2014;383:1490–1502. doi: 10.1016/S0140-6736(13)61649-9.
    1. Yonesaka K, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci. Transl. Med. 2011;3:99ra86. doi: 10.1126/scitranslmed.3002442.
    1. Mohan S, et al. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet. 2014;10:e1004271. doi: 10.1371/journal.pgen.1004271.
    1. Richman SD, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J. Pathol. 2016;238:562–570. doi: 10.1002/path.4679.
    1. Bertotti A, et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1:508–523. doi: 10.1158/-11-0109.
    1. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–337. doi: 10.1038/nature11252.
    1. Luca T, et al. In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells. Cell Prolif. 2014;47:435–447. doi: 10.1111/cpr.12125.
    1. Bekaii-Saab TS, et al. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol. Cancer Ther. 2009;8:2983–2991. doi: 10.1158/1535-7163.MCT-09-0820.
    1. Ramanathan RK, et al. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest. 2004;22:858–865. doi: 10.1081/CNV-200039645.
    1. Leto SM, et al. Sustained inhibition of HER3 and EGFR is necessary to induce regression of HER2-amplified gastrointestinal carcinomas. Clin. Cancer Res. 2015;21:5519–5531. doi: 10.1158/1078-0432.CCR-14-3066.
    1. Meric-Bernstam F, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20:518–530. doi: 10.1016/S1470-2045(18)30904-5.
    1. Sartore-Bianchi A, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:738–746. doi: 10.1016/S1470-2045(16)00150-9.
    1. Fakih MG. Trastuzumab plus pertuzumab resistance does not preclude response to lapatinib plus trastuzumab in HER2-amplified colorectal cancer. Oncologist. 2018;23:474–477. doi: 10.1634/theoncologist.2017-0436.
    1. Wilson CY, Tolias P. Recent advances in cancer drug discovery targeting RAS. Drug Discov. Today. 2016;21:1915–1919. doi: 10.1016/j.drudis.2016.08.002.
    1. Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 2014;4:1269–1280. doi: 10.1158/-14-0462.
    1. Van Cutsem E, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 2011;29:2011–2019. doi: 10.1200/JCO.2010.33.5091.
    1. Amado RG, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008;26:1626–1634. doi: 10.1200/JCO.2007.14.7116.
    1. De Roock W, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010;304:1812–1820. doi: 10.1001/jama.2010.1535.
    1. Peeters M, et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J. Clin. Oncol. 2013;31:759–765. doi: 10.1200/JCO.2012.45.1492.
    1. Douillard JY, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 2013;369:1023–1034. doi: 10.1056/NEJMoa1305275.
    1. Mao C, Yang ZY, Hu XF, Chen Q, Tang JL. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann. Oncol. 2012;23:1518–1525. doi: 10.1093/annonc/mdr464.
    1. De Roock W, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753–762. doi: 10.1016/S1470-2045(10)70130-3.
    1. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Natl Cancer Inst. 2009;101:1308–1324. doi: 10.1093/jnci/djp280.
    1. Laurent-Puig P, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J. Clin. Oncol. 2009;27:5924–5930. doi: 10.1200/JCO.2008.21.6796.
    1. Nagata Y, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6:117–127. doi: 10.1016/j.ccr.2004.06.022.
    1. Moroni M, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005;6:279–286. doi: 10.1016/S1470-2045(05)70102-9.
    1. Sartore-Bianchi A, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J. Clin. Oncol. 2007;25:3238–3245. doi: 10.1200/JCO.2007.11.5956.
    1. Jacobs B, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J. Clin. Oncol. 2009;27:5068–5074. doi: 10.1200/JCO.2008.21.3744.
    1. Khambata-Ford S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 2007;25:3230–3237. doi: 10.1200/JCO.2006.10.5437.
    1. Yu HA, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 2013;19:2240–2247. doi: 10.1158/1078-0432.CCR-12-2246.
    1. Montagut C, et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat. Med. 2012;18:221–223. doi: 10.1038/nm.2609.
    1. Dienstmann R, et al. Safety and activity of the first-in-class Sym004 Anti-EGFR antibody mixture in patients with refractory colorectal cancer. Cancer Discov. 2015;5:598–609. doi: 10.1158/-14-1432.
    1. Montagut C, et al. Efficacy of Sym004 in patients with metastatic colorectal cancer with acquired resistance to anti-EGFR Therapy and molecularly selected by circulating tumor DNA analyses: a Phase 2 Randomized Clinical Trial. JAMA Oncol. 2018;4:e175245. doi: 10.1001/jamaoncol.2017.5245.
    1. Arena S, et al. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Sci. Transl. Med. 2016;8:324ra314. doi: 10.1126/scitranslmed.aad5640.
    1. Scartozzi M, et al. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. Ann. Oncol. 2012;23:1706–1712. doi: 10.1093/annonc/mdr558.
    1. Yang Y, Yee D. Targeting insulin and insulin-like growth factor signaling in breast cancer. J. Mammary Gland Biol. Neoplasia. 2012;17:251–261. doi: 10.1007/s10911-012-9268-y.
    1. Sclafani F, et al. A randomized phase II/III study of dalotuzumab in combination with cetuximab and irinotecan in chemorefractory, KRAS wild-type, metastatic colorectal cancer. J. Natl Cancer Inst. 2015;107:djv258. doi: 10.1093/jnci/djv258.
    1. Reidy DL, et al. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J. Clin. Oncol. 2010;28:4240–4246. doi: 10.1200/JCO.2010.30.4154.
    1. Yar Saglam AS, Alp E, Elmazoglu Z, Menevse S. Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines. Hum. Exp. Toxicol. 2016;35:526–543. doi: 10.1177/0960327115595686.
    1. Li Q, et al. Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer. Sci. Rep. 2015;5:16082. doi: 10.1038/srep16082.
    1. Mahmood MQ, Shukla SD, Dua K, Shastri MD. The role of epidermal growth factor receptor in the management of gastrointestinal carcinomas: present status and future perspectives. Curr. Pharm. Des. 2017;23:2314–2320. doi: 10.2174/1381612823666170124115159.
    1. Saharinen P, Eklund L, Pulkki K, Bono P, Alitalo K. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol. Med. 2011;17:347–362. doi: 10.1016/j.molmed.2011.01.015.
    1. Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat. Rev. Cancer. 2013;13:871–882. doi: 10.1038/nrc3627.
    1. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003;9:669–676. doi: 10.1038/nm0603-669.
    1. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971;285:1182–1186. doi: 10.1056/NEJM197108122850711.
    1. Falcon BL, Chintharlapalli S, Uhlik MT, Pytowski B. Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents. Pharm. Ther. 2016;164:204–225. doi: 10.1016/j.pharmthera.2016.06.001.
    1. Karaman, S., Leppanen, V. M. & Alitalo, K. Vascular endothelial growth factor signaling in development and disease. Development145, dev151019 (2018).
    1. Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb. Perspect. Med. 2012;2:a006502. doi: 10.1101/cshperspect.a006502.
    1. Peng K, Bai Y, Zhu Q, Hu B, Xu Y. Targeting VEGF-neuropilin interactions: a promising antitumor strategy. Drug Discov. Today. 2019;24:656–664. doi: 10.1016/j.drudis.2018.10.004.
    1. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling—in control of vascular function. Nat. Rev. Mol. Cell. Biol. 2006;7:359–371. doi: 10.1038/nrm1911.
    1. Lee YJ, et al. Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment. Cancer Res. 2010;70:8357–8367. doi: 10.1158/0008-5472.CAN-10-1138.
    1. Vaahtomeri K, Karaman S, Makinen T, Alitalo K. Lymphangiogenesis guidance by paracrine and pericellular factors. Genes Dev. 2017;31:1615–1634. doi: 10.1101/gad.303776.117.
    1. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin. Sci. (Lond.) 2005;109:227–241. doi: 10.1042/CS20040370.
    1. Tjwa M, Luttun A, Autiero M, Carmeliet P. VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis. Cell Tissue Res. 2003;314:5–14. doi: 10.1007/s00441-003-0776-3.
    1. Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat. Rev. Cancer. 2008;8:942–956. doi: 10.1038/nrc2524.
    1. Cebe-Suarez S, Zehnder-Fjallman A, Ballmer-Hofer K. The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol. Life Sci. 2006;63:601–615. doi: 10.1007/s00018-005-5426-3.
    1. Garnier L, Gkountidi AO, Hugues S. Tumor-associated lymphatic vessel features and immunomodulatory functions. Front. Immunol. 2019;10:720. doi: 10.3389/fimmu.2019.00720.
    1. Secker GA, Harvey NL. VEGFR signaling during lymphatic vascular development: from progenitor cells to functional vessels. Dev. Dyn. 2015;244:323–331. doi: 10.1002/dvdy.24227.
    1. Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer. 2011;2:1097–1105. doi: 10.1177/1947601911423031.
    1. Lopez A, Harada K, Vasilakopoulou M, Shanbhag N, Ajani JA. Targeting angiogenesis in colorectal carcinoma. Drugs. 2019;79:63–74. doi: 10.1007/s40265-018-1037-9.
    1. Stitzlein L, Rao P, Dudley R. Emerging oral VEGF inhibitors for the treatment of renal cell carcinoma. Expert Opin. Investig. Drugs. 2019;28:121–130. doi: 10.1080/13543784.2019.1559296.
    1. Sammarco Giuseppe, Varricchi Gilda, Ferraro Valentina, Ammendola Michele, De Fazio Michele, Altomare Donato Francesco, Luposella Maria, Maltese Lorenza, Currò Giuseppe, Marone Gianni, Ranieri Girolamo, Memeo Riccardo. Mast Cells, Angiogenesis and Lymphangiogenesis in Human Gastric Cancer. International Journal of Molecular Sciences. 2019;20(9):2106. doi: 10.3390/ijms20092106.
    1. Kurzrock R, Stewart DJ. Exploring the benefit/risk associated with antiangiogenic agents for the treatment of non-small cell lung cancer patients. Clin. Cancer Res. 2017;23:1137–1148. doi: 10.1158/1078-0432.CCR-16-1968.
    1. Seeber A, Gunsilius E, Gastl G, Pircher A. Anti-angiogenics: their value in colorectal cancer therapy. Oncol. Res. Treat. 2018;41:188–193. doi: 10.1159/000488301.
    1. Guba M, Seeliger H, Kleespies A, Jauch KW, Bruns C. Vascular endothelial growth factor in colorectal cancer. Int. J. Colorectal Dis. 2004;19:510–517. doi: 10.1007/s00384-003-0576-y.
    1. Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26:605–622. doi: 10.1016/j.ccell.2014.10.006.
    1. Amelio I, Melino G. The p53 family and the hypoxia-inducible factors (HIFs): determinants of cancer progression. Trends Biochem. Sci. 2015;40:425–434. doi: 10.1016/j.tibs.2015.04.007.
    1. Tarnawski AS, Ahluwalia A, Jones MK. Angiogenesis in gastric mucosa: an important component of gastric erosion and ulcer healing and its impairment in aging. J. Gastroenterol. Hepatol. 2014;29(Suppl. 4):112–123. doi: 10.1111/jgh.12734.
    1. Hurwitz H, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004;350:2335–2342. doi: 10.1056/NEJMoa032691.
    1. Saltz LB, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 2008;26:2013–2019. doi: 10.1200/JCO.2007.14.9930.
    1. Passardi A, et al. Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Ann. Oncol. 2015;26:1201–1207. doi: 10.1093/annonc/mdv130.
    1. Cunningham D, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14:1077–1085. doi: 10.1016/S1470-2045(13)70154-2.
    1. Simkens LH, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015;385:1843–1852. doi: 10.1016/S0140-6736(14)62004-3.
    1. Cremolini C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306–1315. doi: 10.1016/S1470-2045(15)00122-9.
    1. Hurwitz HI, et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist. 2013;18:1004–1012. doi: 10.1634/theoncologist.2013-0107.
    1. Heinemann V, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065–1075. doi: 10.1016/S1470-2045(14)70330-4.
    1. Schwartzberg LS, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J. Clin. Oncol. 2014;32:2240–2247. doi: 10.1200/JCO.2013.53.2473.
    1. Venook AP, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a Randomized Clinical Trial. JAMA. 2017;317:2392–2401. doi: 10.1001/jama.2017.7105.
    1. Parikh AR, et al. MAVERICC, a randomized, biomarker-stratified, phase II study of mFOLFOX6-bevacizumab versus FOLFIRI-bevacizumab as first-line chemotherapy in metastatic colorectal cancer. Clin. Cancer Res. 2019;25:2988–2995. doi: 10.1158/1078-0432.CCR-18-1221.
    1. Yamazaki K, et al. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G) Ann. Oncol. 2016;27:1539–1546. doi: 10.1093/annonc/mdw206.
    1. Giantonio BJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 2007;25:1539–1544. doi: 10.1200/JCO.2006.09.6305.
    1. Bennouna J, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14:29–37. doi: 10.1016/S1470-2045(12)70477-1.
    1. Grothey A, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) J. Clin. Oncol. 2008;26:5326–5334. doi: 10.1200/JCO.2008.16.3212.
    1. Goey KKH, et al. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study. Ann. Oncol. 2017;28:2128–2134. doi: 10.1093/annonc/mdx322.
    1. Diaz-Rubio E, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist. 2012;17:15–25. doi: 10.1634/theoncologist.2011-0249.
    1. Koeberle D, et al. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06) Ann. Oncol. 2015;26:709–714. doi: 10.1093/annonc/mdv011.
    1. Yalcin S, et al. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III ‘Stop and Go’ study results—a Turkish Oncology Group Trial. Oncology. 2013;85:328–335. doi: 10.1159/000355914.
    1. Hegewisch-Becker S, et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2015;16:1355–1369. doi: 10.1016/S1470-2045(15)00042-X.
    1. Tang PA, et al. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. Clin. Cancer Res. 2012;18:6023–6031. doi: 10.1158/1078-0432.CCR-11-3252.
    1. Van Cutsem E, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 2012;30:3499–3506. doi: 10.1200/JCO.2012.42.8201.
    1. Folprecht G, et al. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. Ann. Oncol. 2016;27:1273–1279. doi: 10.1093/annonc/mdw176.
    1. Tabernero J, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16:499–508. doi: 10.1016/S1470-2045(15)70127-0.
    1. Moore M, et al. Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. Ann. Oncol. 2016;27:2216–2224. doi: 10.1093/annonc/mdw412.
    1. Argiles G, et al. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: a phase II trial. Eur. J. Cancer. 2015;51:942–949. doi: 10.1016/j.ejca.2015.02.013.
    1. Grothey A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–312. doi: 10.1016/S0140-6736(12)61900-X.
    1. Li J, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16:619–629. doi: 10.1016/S1470-2045(15)70156-7.
    1. Li J, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO Randomized Clinical Trial. JAMA. 2018;319:2486–2496. doi: 10.1001/jama.2018.7855.
    1. Xu RH, et al. Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial. Chin. J. Cancer. 2017;36:97. doi: 10.1186/s40880-017-0263-y.
    1. Siu LL, et al. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial. J. Clin. Oncol. 2013;31:2477–2484. doi: 10.1200/JCO.2012.46.0543.
    1. Schmoll HJ, et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III) J. Clin. Oncol. 2012;30:3588–3595. doi: 10.1200/JCO.2012.42.5355.
    1. Hoff PM, et al. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II) J. Clin. Oncol. 2012;30:3596–3603. doi: 10.1200/JCO.2012.42.6031.
    1. Van Cutsem E, et al. Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study. Ann. Oncol. 2018;29:1955–1963. doi: 10.1093/annonc/mdy241.
    1. Kopetz S, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J. Clin. Oncol. 2010;28:453–459. doi: 10.1200/JCO.2009.24.8252.
    1. Chiron M, et al. Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer. Mol. Cancer Ther. 2014;13:1636–1644. doi: 10.1158/1535-7163.MCT-13-0753.
    1. Goede V, et al. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br. J. Cancer. 2010;103:1407–1414. doi: 10.1038/sj.bjc.6605925.
    1. Rigamonti N, et al. Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. Cell Rep. 2014;8:696–706. doi: 10.1016/j.celrep.2014.06.059.
    1. Scholz A, et al. Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. EMBO Mol. Med. 2016;8:39–57. doi: 10.15252/emmm.201505505.
    1. Kienast Y, et al. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin. Cancer Res. 2013;19:6730–6740. doi: 10.1158/1078-0432.CCR-13-0081.
    1. Mueller, T., Freystein, J., Lucas, H. & Schmoll, H. J. Efficacy of a bispecific antibody co-targeting VEGFA and Ang-2 in combination with chemotherapy in a chemoresistant colorectal carcinoma xenograft model. Molecules24, 2865 (2019).
    1. Hidalgo M, et al. First-in-human phase I study of single-agent vanucizumab, a first-in-class bispecific anti-angiopoietin-2/anti-VEGF-A antibody, in adult patients with advanced solid tumors. Clin. Cancer Res. 2018;24:1536–1545. doi: 10.1158/1078-0432.CCR-17-1588.
    1. Mitsuhashi A, et al. Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab. Nat. Commun. 2015;6:8792. doi: 10.1038/ncomms9792.
    1. Incio Joao, Ligibel Jennifer A., McManus Daniel T., Suboj Priya, Jung Keehoon, Kawaguchi Kosuke, Pinter Matthias, Babykutty Suboj, Chin Shan M., Vardam Trupti D., Huang Yuhui, Rahbari Nuh N., Roberge Sylvie, Wang Dannie, Gomes-Santos Igor L., Puchner Stefan B., Schlett Christopher L., Hoffmman Udo, Ancukiewicz Marek, Tolaney Sara M., Krop Ian E., Duda Dan G., Boucher Yves, Fukumura Dai, Jain Rakesh K. Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. Science Translational Medicine. 2018;10(432):eaag0945. doi: 10.1126/scitranslmed.aag0945.
    1. Goto, H. & Nishioka, Y. Fibrocytes: a novel stromal cells to regulate resistance to anti-angiogenic therapy and cancer progression. Int. J. Mol. Sci. 19, 98 (2017).
    1. Semrad TJ, et al. Phase II study of dovitinib in patients progressing on anti-vascular endothelial growth factor therapy. Cancer Treat. Res. Commun. 2017;10:21–26. doi: 10.1016/j.ctarc.2016.12.002.
    1. Jahangiri A, et al. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin. Cancer Res. 2013;19:1773–1783. doi: 10.1158/1078-0432.CCR-12-1281.
    1. Wakelee H, et al. Efficacy and safety of onartuzumab in combination with first-line bevacizumab- or pemetrexed-based chemotherapy regimens in advanced non-squamous non-small-cell lung cancer. Clin. Lung Cancer. 2017;18:50–59. doi: 10.1016/j.cllc.2016.09.013.
    1. Prete A, et al. Pericytes elicit resistance to vemurafenib and sorafenib therapy in thyroid carcinoma via the TSP-1/TGFbeta1 axis. Clin. Cancer Res. 2018;24:6078–6097. doi: 10.1158/1078-0432.CCR-18-0693.
    1. Carbone C, et al. Combined inhibition of IL1, CXCR1/2, and TGFbeta signaling pathways modulates in-vivo resistance to anti-VEGF treatment. Anticancer Drugs. 2016;27:29–40. doi: 10.1097/CAD.0000000000000301.
    1. Castro BA, et al. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy. Oncogene. 2017;36:3749–3759. doi: 10.1038/onc.2017.1.
    1. Liu T, et al. PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma. Nat. Commun. 2018;9:3439. doi: 10.1038/s41467-018-05982-z.
    1. Stintzing S, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol. 2016;17:1426–1434. doi: 10.1016/S1470-2045(16)30269-8.
    1. Khattak MA, Martin H, Davidson A, Phillips M. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials. Clin. Colorectal Cancer. 2015;14:81–90. doi: 10.1016/j.clcc.2014.12.011.
    1. Arnold D, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann. Oncol. 2017;28:1713–1729. doi: 10.1093/annonc/mdx175.
    1. Tejpar S, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol. 2017;3:194–201. doi: 10.1001/jamaoncol.2016.3797.
    1. Boeckx N, et al. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Ann. Oncol. 2017;28:1862–1868. doi: 10.1093/annonc/mdx119.
    1. Hecht JR, et al. SPIRITT: a randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer. Clin. Colorectal Cancer. 2015;14:72–80. doi: 10.1016/j.clcc.2014.12.009.
    1. Wang Q, Yang S, Wang K, Sun SY. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J. Hematol. Oncol. 2019;12:63. doi: 10.1186/s13045-019-0759-9.
    1. Cheng F, Guo D. MET in glioma: signaling pathways and targeted therapies. J. Exp. Clin. Cancer Res. 2019;38:270. doi: 10.1186/s13046-019-1269-x.
    1. Demkova L, Kucerova L. Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma. Mol. Cancer. 2018;17:26. doi: 10.1186/s12943-018-0795-z.
    1. Lam BQ, Dai L, Qin Z. The role of HGF/c-MET signaling pathway in lymphoma. J. Hematol. Oncol. 2016;9:135. doi: 10.1186/s13045-016-0366-y.
    1. Bradley CA, et al. Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. Nat. Rev. Clin. Oncol. 2017;14:562–576. doi: 10.1038/nrclinonc.2017.40.
    1. Cooper CS, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 1984;311:29–33. doi: 10.1038/311029a0.
    1. Nakamura T, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989;342:440–443. doi: 10.1038/342440a0.
    1. Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature. 1987;327:239–242. doi: 10.1038/327239a0.
    1. Schmidt C, et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature. 1995;373:699–702. doi: 10.1038/373699a0.
    1. Xing F, et al. Activation of the c-Met pathway mobilizes an inflammatory network in the brain microenvironment to promote brain metastasis of breast cancer. Cancer Res. 2016;76:4970–4980. doi: 10.1158/0008-5472.CAN-15-3541.
    1. Ozawa Y, et al. c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target. BMC Cancer. 2015;15:451. doi: 10.1186/s12885-015-1450-3.
    1. Anestis A, Zoi I, Karamouzis MV. Current advances of targeting HGF/c-Met pathway in gastric cancer. Ann. Transl. Med. 2018;6:247. doi: 10.21037/atm.2018.04.42.
    1. Safaie QE, et al. The c-Met receptor: implication for targeted therapies in colorectal cancer. Tumour Biol. 2017;39:1010428317699118.
    1. Otte JM, et al. Functional expression of HGF and its receptor in human colorectal cancer. Digestion. 2000;61:237–246. doi: 10.1159/000007764.
    1. Matsumoto K, Umitsu M, De Silva DM, Roy A, Bottaro DP. Hepatocyte growth factor/MET in cancer progression and biomarker discovery. Cancer Sci. 2017;108:296–307. doi: 10.1111/cas.13156.
    1. Bahrami A, et al. C-Met as a potential target for the treatment of gastrointestinal cancer: current status and future perspectives. J. Cell Physiol. 2017;232:2657–2673. doi: 10.1002/jcp.25794.
    1. Bouattour M, et al. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma. Hepatology. 2018;67:1132–1149. doi: 10.1002/hep.29496.
    1. Drilon A, Cappuzzo F, Ou SI, Camidge DR. Targeting MET in lung cancer: will expectations finally be MET? J. Thorac. Oncol. 2017;12:15–26. doi: 10.1016/j.jtho.2016.10.014.
    1. Blumenschein GR, Jr., Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J. Clin. Oncol. 2012;30:3287–3296. doi: 10.1200/JCO.2011.40.3774.
    1. Cabanillas ME, et al. Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: results of a multicenter phase II International Thyroid Oncology Group Trial. J. Clin. Oncol. 2017;35:3315–3321. doi: 10.1200/JCO.2017.73.0226.
    1. Linehan WM, et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N. Engl. J. Med. 2016;374:135–145. doi: 10.1056/NEJMoa1505917.
    1. Catenacci DVT, et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1467–1482. doi: 10.1016/S1470-2045(17)30566-1.
    1. Sartore-Bianchi A, Loupakis F, Argiles G, Prager GW. Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. Ann. Oncol. 2016;27:1456–1466. doi: 10.1093/annonc/mdw191.
    1. Gao H, Guan M, Sun Z, Bai C. High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis. Tumour Biol. 2015;36:515–520. doi: 10.1007/s13277-014-2659-5.
    1. Luo HY, Xu RH. Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. World J. Gastroenterol. 2014;20:3858–3874. doi: 10.3748/wjg.v20.i14.3858.
    1. Baldus SE, Kort EJ, Schirmacher P, Dienes HP, Resau JH. Quantification of MET and hepatocyte growth factor/scatter factor expression in colorectal adenomas, carcinomas and non-neoplastic epithelia by quantitative laser scanning microscopy. Int. J. Oncol. 2007;31:199–204.
    1. Mo HN, Liu P. Targeting MET in cancer therapy. Chronic Dis. Transl. Med. 2017;3:148–153. doi: 10.1016/j.cdtm.2017.06.002.
    1. Kentsis A, et al. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat. Med. 2012;18:1118–1122. doi: 10.1038/nm.2819.
    1. Lennerz JK, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J. Clin. Oncol. 2011;29:4803–4810. doi: 10.1200/JCO.2011.35.4928.
    1. Kammula US, et al. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett. 2007;248:219–228. doi: 10.1016/j.canlet.2006.07.007.
    1. El-Deiry WS, et al. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer Biol. Ther. 2015;16:1726–1737. doi: 10.1080/15384047.2015.1113356.
    1. Di Renzo MF, et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin. Cancer Res. 1995;1:147–154.
    1. Boccaccio C, Gaudino G, Gambarotta G, Galimi F, Comoglio PM. Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF. J. Biol. Chem. 1994;269:12846–12851.
    1. Stellrecht CM, Gandhi V. MET receptor tyrosine kinase as a therapeutic anticancer target. Cancer Lett. 2009;280:1–14. doi: 10.1016/j.canlet.2008.10.045.
    1. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. 2008;7:504–516. doi: 10.1038/nrd2530.
    1. Pennacchietti S, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003;3:347–361. doi: 10.1016/S1535-6108(03)00085-0.
    1. Bigatto V, et al. TNF-alpha promotes invasive growth through the MET signaling pathway. Mol. Oncol. 2015;9:377–388. doi: 10.1016/j.molonc.2014.09.002.
    1. Qi J, et al. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res. 2011;71:1081–1091. doi: 10.1158/0008-5472.CAN-10-1623.
    1. Peacock JW, et al. SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1. EMBO Mol. Med. 2018;10:219–238. doi: 10.15252/emmm.201707689.
    1. Worzfeld T, et al. ErbB-2 signals through Plexin-B1 to promote breast cancer metastasis. J. Clin. Invest. 2012;122:1296–1305. doi: 10.1172/JCI60568.
    1. Malik MF, Ye L, Jiang WG. The Plexin-B family and its role in cancer progression. Histol. Histopathol. 2014;29:151–165.
    1. Stein U, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat. Med. 2009;15:59–67. doi: 10.1038/nm.1889.
    1. Parseghian CM, Napolitano S, Loree JM, Kopetz S. Mechanisms of innate and acquired resistance to anti-EGFR therapy: a review of current knowledge with a focus on rechallenge therapies. Clin. Cancer Res. 2019;25:6899–6908. doi: 10.1158/1078-0432.CCR-19-0823.
    1. Boccaccio C, Luraghi P, Comoglio PM. MET-mediated resistance to EGFR inhibitors: an old liaison rooted in colorectal cancer stem cells. Cancer Res. 2014;74:3647–3651. doi: 10.1158/0008-5472.CAN-14-1088.
    1. Murtuza A, et al. Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. Cancer Res. 2019;79:689–698. doi: 10.1158/0008-5472.CAN-18-1281.
    1. Luraghi P, et al. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer Res. 2014;74:1857–1869. doi: 10.1158/0008-5472.CAN-13-2340-T.
    1. Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S, Bardelli A. Acquired resistance to EGFR-targeted therapies in colorectal cancer. Mol. Oncol. 2014;8:1084–1094. doi: 10.1016/j.molonc.2014.05.003.
    1. Viticchie G, Muller PAJ. c-Met and other cell surface molecules: interaction, activation and functional consequences. Biomedicines. 2015;3:46–70. doi: 10.3390/biomedicines3010046.
    1. Tanizaki J, Okamoto I, Sakai K, Nakagawa K. Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. Br. J. Cancer. 2011;105:807–813. doi: 10.1038/bjc.2011.322.
    1. Song EK, et al. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. Int. J. Cancer. 2015;136:1967–1975. doi: 10.1002/ijc.29225.
    1. Nandagopal L, Sonpavde GP, Agarwal N. Investigational MET inhibitors to treat renal cell carcinoma. Expert Opin. Investig. Drugs. 2019;28:851–860. doi: 10.1080/13543784.2019.1673366.
    1. Reid JC, et al. In vitro evidence that KLK14 regulates the components of the HGF/Met axis, pro-HGF and HGF-activator inhibitor 1A and 1B. Biol. Chem. 2016;397:1299–1305. doi: 10.1515/hsz-2016-0163.
    1. Ye F, et al. 3-Cl-AHPC inhibits pro-HGF maturation by inducing matriptase/HAI-1 complex formation. J. Cell Mol. Med. 2019;23:155–166. doi: 10.1111/jcmm.13900.
    1. Hu C, et al. Expression of hepatocyte growth factor activator inhibitor-1 (HAI-1) gene in prostate cancer: clinical and biological significance. J. Buon. 2014;19:215–220.
    1. Tsai CH, et al. HAI-2 suppresses the invasive growth and metastasis of prostate cancer through regulation of matriptase. Oncogene. 2014;33:4643–4652. doi: 10.1038/onc.2013.412.
    1. Garajova I, Giovannetti E, Biasco G, Peters GJ. c-Met as a target for personalized therapy. Transl. Oncogenom. 2015;7:13–31.
    1. Ishikawa T, Kimura Y, Hirano H, Higashi S. Matrix metalloproteinase-7 induces homotypic tumor cell aggregation via proteolytic cleavage of the membrane-bound Kunitz-type inhibitor HAI-1. J. Biol. Chem. 2017;292:20769–20784. doi: 10.1074/jbc.M117.796789.
    1. Iveson T, et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol. 2014;15:1007–1018. doi: 10.1016/S1470-2045(14)70023-3.
    1. Doi T, et al. A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The RILOMET-2 trial. J. Clin. Oncol. 2015;33:TPS226–TPS226. doi: 10.1200/jco.2015.33.3_suppl.tps226.
    1. Van Cutsem E, et al. Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clin. Cancer Res. 2014;20:4240–4250. doi: 10.1158/1078-0432.CCR-13-2752.
    1. Tabernero J, et al. A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases. Clin. Cancer Res. 2014;20:2793–2804. doi: 10.1158/1078-0432.CCR-13-1837.
    1. Jones SF, et al. Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study. J. Clin. Oncol. 2010;28:3081–3081. doi: 10.1200/jco.2010.28.15_suppl.3081.
    1. Hori A, et al. Monotherapeutic and combination antitumor activities of TAK-701, a humanized anti-hepatocyte growth factor neutralizing antibody, against multiple types of cancer. Cancer Res. 2009;69:1244.
    1. Okamoto W, et al. TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Mol. Cancer Ther. 2010;9:2785–2792. doi: 10.1158/1535-7163.MCT-10-0481.
    1. Merchant M, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc. Natl Acad. Sci. USA. 2013;110:E2987–E2996. doi: 10.1073/pnas.1302725110.
    1. Shah MA, et al. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the METGastric Randomized Clinical Trial. JAMA Oncol. 2017;3:620–627. doi: 10.1001/jamaoncol.2016.5580.
    1. Spigel DR, et al. Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung. J. Clin. Oncol. 2017;35:412–420. doi: 10.1200/JCO.2016.69.2160.
    1. Cloughesy T, et al. Randomized, double-blind, placebo-controlled, multicenter phase II study of onartuzumab plus bevacizumab versus placebo plus bevacizumab in patients with recurrent glioblastoma: efficacy, safety, and hepatocyte growth factor and O(6)-methylguanine-DNA methyltransferase biomarker analyses. J. Clin. Oncol. 2017;35:343–351. doi: 10.1200/JCO.2015.64.7685.
    1. Bendell JC, et al. A phase II randomized trial (GO27827) of first-line FOLFOX plus bevacizumab with or without the MET inhibitor onartuzumab in patients with metastatic colorectal cancer. Oncologist. 2017;22:264–271. doi: 10.1634/theoncologist.2016-0223.
    1. Pacchiana G, et al. Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. J. Biol. Chem. 2010;285:36149–36157. doi: 10.1074/jbc.M110.134031.
    1. Strickler JH, et al. First-in-human phase I, dose-escalation and -expansion study of telisotuzumab vedotin, an antibody–drug conjugate targeting c-Met, in patients with advanced solid tumors. J. Clin. Oncol. 2018;36:3298–3306. doi: 10.1200/JCO.2018.78.7697.
    1. Wang J, et al. ABBV-399, a c-Met antibody-drug conjugate that targets both MET-amplified and c-Met-overexpressing tumors, irrespective of MET pathway dependence. Clin. Cancer Res. 2017;23:992–1000. doi: 10.1158/1078-0432.CCR-16-1568.
    1. Wang J, et al. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification. BMC Cancer. 2016;16:105. doi: 10.1186/s12885-016-2138-z.
    1. Scagliotti G, et al. A randomized-controlled phase 2 study of the MET antibody emibetuzumab in combination with erlotinib as first-line treatment for EGFR mutation-positive NSCLC patients. J. Thorac. Oncol. 2020;15:80–90. doi: 10.1016/j.jtho.2019.10.003.
    1. Rosen LS, et al. A first-in-human phase I study of a bivalent MET antibody, emibetuzumab (LY2875358), as monotherapy and in combination with erlotinib in advanced cancer. Clin. Cancer Res. 2017;23:1910–1919. doi: 10.1158/1078-0432.CCR-16-1418.
    1. Harding JJ, et al. A phase Ib/II study of ramucirumab in combination with emibetuzumab in patients with advanced cancer. Clin. Cancer Res. 2019;25:5202–5211. doi: 10.1158/1078-0432.CCR-18-4010.
    1. Sakai D, et al. A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer. Cancer Chemother. Pharm. 2017;80:1197–1207. doi: 10.1007/s00280-017-3445-z.
    1. Li H, et al. MET inhibitors promote liver tumor evasion of the immune response by stabilizing PDL1. Gastroenterology. 2019;156:1849–1861.e1813. doi: 10.1053/j.gastro.2019.01.252.
    1. Zaman S, et al. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells. Neoplasia. 2015;17:289–300. doi: 10.1016/j.neo.2015.01.006.
    1. Remsing Rix LL, et al. GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells. ACS Chem. Biol. 2014;9:353–358. doi: 10.1021/cb400660a.
    1. L R, et al. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 2018;19:682–693. doi: 10.1016/S1470-2045(18)30146-3.
    1. Scagliotti GV, et al. Tivantinib in combination with erlotinib versus erlotinib alone for EGFR-mutant NSCLC: an exploratory analysis of the phase 3 MARQUEE study. J. Thorac. Oncol. 2018;13:849–854. doi: 10.1016/j.jtho.2017.12.009.
    1. Eng C, et al. A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy. Int. J. Cancer. 2016;139:177–186. doi: 10.1002/ijc.30049.
    1. Scagliotti G, et al. Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 2015;33:2667–2674. doi: 10.1200/JCO.2014.60.7317.
    1. Rimassa L, et al. Phase II study of tivantinib and cetuximab in patients with KRAS wild-type metastatic colorectal cancer with acquired resistance to EGFR inhibitors and emergence of MET overexpression: lesson learned for future trials with EGFR/MET dual inhibition. Clin. Colorectal Cancer. 2019;18:125–132.e122. doi: 10.1016/j.clcc.2019.02.004.
    1. Van Cutsem E, et al. A multicenter phase II study of AMG 337 in patients with -amplified gastric/gastroesophageal junction/esophageal adenocarcinoma and other -amplified solid tumors. Clin. Cancer Res. 2019;25:2414–2423. doi: 10.1158/1078-0432.CCR-18-1337.
    1. Hong DS, et al. Phase I study of AMG 337, a highly selective small-molecule MET inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 2019;25:2403–2413. doi: 10.1158/1078-0432.CCR-18-1341.
    1. Collie GW, et al. Structural and molecular insight into resistance mechanisms of first generation cMET inhibitors. ACS Med. Chem. Lett. 2019;10:1322–1327. doi: 10.1021/acsmedchemlett.9b00276.
    1. Gan HK, et al. First-in-human phase I study of the selective MET inhibitor, savolitinib, in patients with advanced solid tumors: safety, pharmacokinetics, and antitumor activity. Clin. Cancer Res. 2019;25:4924–4932. doi: 10.1158/1078-0432.CCR-18-1189.
    1. Yl W, et al. Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer. J. Clin. Oncol. 2018;36:3101–3109. doi: 10.1200/JCO.2018.77.7326.
    1. Roskoski R., Jr. Properties of FDA-approved small molecule protein kinase inhibitors. Pharm. Res. 2019;144:19–50. doi: 10.1016/j.phrs.2019.03.006.
    1. Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019;322:764–774. doi: 10.1001/jama.2019.11058.
    1. Lev A, et al. Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer. Cancer Biol. Ther. 2017;18:694–704. doi: 10.1080/15384047.2017.1364323.
    1. Choueiri TK, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17:917–927. doi: 10.1016/S1470-2045(16)30107-3.
    1. Abou-Alfa GK, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 2018;379:54–63. doi: 10.1056/NEJMoa1717002.
    1. Cabanillas ME, Ryder M, Jimenez C. Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr. Rev. 2019;40:1573–1604. doi: 10.1210/er.2019-00007.
    1. Scott AJ, et al. Cabozantinib exhibits potent antitumor activity in colorectal cancer patient-derived tumor xenograft models via autophagy and signaling mechanisms. Mol. Cancer Ther. 2018;17:2112–2122. doi: 10.1158/1535-7163.MCT-17-0131.
    1. Yang, S. et al. Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway. Cancer Gene Ther. 10.1038/s41417-019-0098-6 (2019).
    1. He AR, et al. First-in-human phase I study of merestinib, an oral multikinase inhibitor, in patients with advanced cancer. Oncologist. 2019;24:e930–e942. doi: 10.1634/theoncologist.2018-0411.
    1. Shah MA, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS ONE. 2013;8:e54014. doi: 10.1371/journal.pone.0054014.
    1. Engstrom LD, et al. Glesatinib exhibits antitumor activity in lung cancer models and patients harboring exon 14 mutations and overcomes mutation-mediated resistance to type I MET inhibitors in nonclinical models. Clin. Cancer Res. 2017;23:6661–6672. doi: 10.1158/1078-0432.CCR-17-1192.
    1. Molife LR, et al. A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors. Clin. Cancer Res. 2014;20:6284–6294. doi: 10.1158/1078-0432.CCR-14-0409.
    1. Friese-Hamim M, Bladt F, Locatelli G, Stammberger U, Blaukat A. The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models. Am. J. Cancer Res. 2017;7:962–972.
    1. Dolan M, et al. Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance. PLoS ONE. 2019;14:e0220101. doi: 10.1371/journal.pone.0220101.
    1. Yoshioka H, et al. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study) Ann. Oncol. 2015;26:2066–2072. doi: 10.1093/annonc/mdv288.
    1. Ciamporcero E, et al. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol. Cancer Ther. 2015;14:101–110. doi: 10.1158/1535-7163.MCT-14-0094.
    1. Kim DC, et al. Resistance to the c-Met inhibitor KRC-108 induces the epithelial transition of gastric cancer cells. Oncol. Lett. 2016;11:991–997. doi: 10.3892/ol.2015.4029.
    1. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat. Rev. Immunol. 2002;2:116–126. doi: 10.1038/nri727.
    1. Jelinek T, Mihalyova J, Kascak M, Duras J, Hajek R. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. Immunology. 2017;152:357–371. doi: 10.1111/imm.12788.
    1. Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J. Clin. Invest. 2015;125:3384–3391. doi: 10.1172/JCI80011.
    1. Markman JL, Shiao SL. Impact of the immune system and immunotherapy in colorectal cancer. J. Gastrointest. Oncol. 2015;6:208–223.
    1. Wang J, Reiss KA, Khatri R, Jaffee E, Laheru D. Immune Therapy in GI malignancies: a review. J. Clin. Oncol. 2015;33:1745–1753. doi: 10.1200/JCO.2015.60.7879.
    1. Kalyan A, Kircher S, Shah H, Mulcahy M, Benson A. Updates on immunotherapy for colorectal cancer. J. Gastrointest. Oncol. 2018;9:160–169. doi: 10.21037/jgo.2018.01.17.
    1. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat. Rev. Cancer. 2019;19:133–150. doi: 10.1038/s41568-019-0116-x.
    1. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–899. doi: 10.1016/j.cell.2010.01.025.
    1. Ishihara Jun, Ishihara Ako, Sasaki Koichi, Lee Steve Seung-Young, Williford John-Michael, Yasui Mariko, Abe Hiroyuki, Potin Lambert, Hosseinchi Peyman, Fukunaga Kazuto, Raczy Michal M., Gray Laura T., Mansurov Aslan, Katsumata Kiyomitsu, Fukayama Masashi, Kron Stephen J., Swartz Melody A., Hubbell Jeffrey A. Targeted antibody and cytokine cancer immunotherapies through collagen affinity. Science Translational Medicine. 2019;11(487):eaau3259. doi: 10.1126/scitranslmed.aau3259.
    1. Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36:265–276. doi: 10.1016/j.it.2015.02.008.
    1. Gianchecchi E, Delfino DV, Fierabracci A. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun. Rev. 2013;12:1091–1100. doi: 10.1016/j.autrev.2013.05.003.
    1. Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front. Oncol. 2018;8:86. doi: 10.3389/fonc.2018.00086.
    1. Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J. Exp. Clin. Cancer Res. 2019;38:255. doi: 10.1186/s13046-019-1259-z.
    1. Wang HB, et al. Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy. J. Dig. Dis. 2017;18:574–581. doi: 10.1111/1751-2980.12538.
    1. Berntsson J, Nodin B, Eberhard J, Micke P, Jirstrom K. Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer. Int. J. Cancer. 2016;139:1129–1139. doi: 10.1002/ijc.30138.
    1. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 2013;14:1014–1022. doi: 10.1038/ni.2703.
    1. Zhang X, Kelaria S, Kerstetter J, Wang J. The functional and prognostic implications of regulatory T cells in colorectal carcinoma. J. Gastrointest. Oncol. 2015;6:307–313.
    1. Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 2012;72:2162–2171. doi: 10.1158/0008-5472.CAN-11-3687.
    1. Fujimoto H, et al. Deregulated mucosal immune surveillance through gut-associated regulatory T cells and PD-1(+) T cells in human colorectal cancer. J. Immunol. 2018;200:3291–3303. doi: 10.4049/jimmunol.1701222.
    1. Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat. Rev. Cancer. 2016;16:7–19. doi: 10.1038/nrc.2015.5.
    1. Liu Y, et al. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. Oncogene. 2017;36:6143–6153. doi: 10.1038/onc.2017.209.
    1. Juneja VR, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J. Exp. Med. 2017;214:895–904. doi: 10.1084/jem.20160801.
    1. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 2012;24:207–212. doi: 10.1016/j.coi.2011.12.009.
    1. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734–1736. doi: 10.1126/science.271.5256.1734.
    1. Robert C, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 2015;372:2521–2532. doi: 10.1056/NEJMoa1503093.
    1. Herbst RS, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–1550. doi: 10.1016/S0140-6736(15)01281-7.
    1. Motzer RJ, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 2015;373:1803–1813. doi: 10.1056/NEJMoa1510665.
    1. Robert C, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2015;372:320–330. doi: 10.1056/NEJMoa1412082.
    1. Brahmer J, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 2015;373:123–135. doi: 10.1056/NEJMoa1504627.
    1. Borghaei H, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 2015;373:1627–1639. doi: 10.1056/NEJMoa1507643.
    1. Ganesh K, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat. Rev. Gastroenterol. Hepatol. 2019;16:361–375. doi: 10.1038/s41575-019-0126-x.
    1. Tintelnot J, Stein A. Immunotherapy in colorectal cancer: available clinical evidence, challenges and novel approaches. World J. Gastroenterol. 2019;25:3920–3928. doi: 10.3748/wjg.v25.i29.3920.
    1. Hoos A, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin. Oncol. 2010;37:533–546. doi: 10.1053/j.seminoncol.2010.09.015.
    1. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010;363:711–723. doi: 10.1056/NEJMoa1003466.
    1. Wolchok JD, et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013;369:122–133. doi: 10.1056/NEJMoa1302369.
    1. Overman MJ, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182–1191. doi: 10.1016/S1470-2045(17)30422-9.
    1. Passardi, A., Canale, M., Valgiusti, M. & Ulivi, P. Immune checkpoints as a target for colorectal cancer treatment. Int. J. Mol. Sci.18, 1324 (2017).
    1. Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012;366:2455–2465. doi: 10.1056/NEJMoa1200694.
    1. Giannakis M, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 2016;15:857–865. doi: 10.1016/j.celrep.2016.03.075.
    1. Llosa NJ, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43–51. doi: 10.1158/-14-0863.
    1. Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 2015;372:2509–2520. doi: 10.1056/NEJMoa1500596.
    1. Snyder A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 2014;371:2189–2199. doi: 10.1056/NEJMoa1406498.
    1. Ready N, et al. First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers. J. Clin. Oncol. 2019;37:992–1000. doi: 10.1200/JCO.18.01042.
    1. Mouw KW, Goldberg MS, Konstantinopoulos PA, D’Andrea AD. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov. 2017;7:675–693. doi: 10.1158/-17-0226.
    1. McGranahan N, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463–1469. doi: 10.1126/science.aaf1490.
    1. Alexandrov LB, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–421. doi: 10.1038/nature12477.
    1. O’Neil BH, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PLoS ONE. 2017;12:e0189848. doi: 10.1371/journal.pone.0189848.
    1. Le DT, et al. KEYNOTE-164: pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer. J. Clin. Oncol. 2018;36:3514–3514. doi: 10.1200/JCO.2018.36.15_suppl.3514.
    1. Le Dung T., Kim Tae Won, Van Cutsem Eric, Geva Ravit, Jäger Dirk, Hara Hiroki, Burge Matthew, O’Neil Bert, Kavan Petr, Yoshino Takayuki, Guimbaud Rosine, Taniguchi Hiroya, Elez Elena, Al-Batran Salah-Eddin, Boland Patrick M., Crocenzi Todd, Atreya Chloe E., Cui Yi, Dai Tong, Marinello Patricia, Diaz Jr Luis A., André Thierry. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164. Journal of Clinical Oncology. 2020;38(1):11–19. doi: 10.1200/JCO.19.02107.
    1. Le DT, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–413. doi: 10.1126/science.aan6733.
    1. Long GV, et al. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 2017;18:1202–1210. doi: 10.1016/S1470-2045(17)30428-X.
    1. Overman MJ, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J. Clin. Oncol. 2018;36:773–779. doi: 10.1200/JCO.2017.76.9901.
    1. Lenz H.-J.J., Van Cutsem E., Limon M.L., Wong K.Y., Hendlisz A., Aglietta M., Garcia-Alfonso P., Neyns B., Luppi G., Cardin D., Dragovich T., Shah U., Atasoy A., Postema R., Boyd Z., Ledeine J.-M., Overman M., Lonardi S. Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) Annals of Oncology. 2018;29:viii714. doi: 10.1093/annonc/mdy424.019.
    1. Morse MA, et al. Safety of nivolumab plus low-dose ipilimumab in previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Oncologist. 2019;24:1453–1461. doi: 10.1634/theoncologist.2019-0129.
    1. Zhou E, et al. Up-regulation of Tim-3 is associated with poor prognosis of patients with colon cancer. Int. J. Clin. Exp. Pathol. 2015;8:8018–8027.
    1. Yu X, et al. Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy. MABS. 2019;11:1139–1148. doi: 10.1080/19420862.2019.1629239.
    1. Lee JJ, Chu E. Recent advances in the clinical development of immune checkpoint blockade therapy for mismatch repair proficient (pMMR)/non-MSI-H metastatic colorectal cancer. Clin. Colorectal Cancer. 2018;17:258–273. doi: 10.1016/j.clcc.2018.06.004.
    1. Wu X, et al. Application of PD-1 Blockade in Cancer Immunotherapy. Comput. Struct. Biotechnol. J. 2019;17:661–674. doi: 10.1016/j.csbj.2019.03.006.
    1. Twyman-Saint Victor C, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373–377. doi: 10.1038/nature14292.
    1. Segal, N. H. et al. 403P Phase I studies of the novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab: preliminary efficacy and safety in patients (pts) with metastatic colorectal cancer (mCRC). Ann. Oncol.28, 10.1093/annonc/mdx367.036 (2017).
    1. Tabernero J, et al. Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC) J. Clin. Oncol. 2017;35:3002–3002. doi: 10.1200/JCO.2017.35.15_suppl.3002.
    1. Bacac M, et al. A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors. Clin. Cancer Res. 2016;22:3286–3297. doi: 10.1158/1078-0432.CCR-15-1696.
    1. Claus Christina, Ferrara Claudia, Xu Wei, Sam Johannes, Lang Sabine, Uhlenbrock Franziska, Albrecht Rosmarie, Herter Sylvia, Schlenker Ramona, Hüsser Tamara, Diggelmann Sarah, Challier John, Mössner Ekkehard, Hosse Ralf J., Hofer Thomas, Brünker Peter, Joseph Catherine, Benz Jörg, Ringler Philippe, Stahlberg Henning, Lauer Matthias, Perro Mario, Chen Stanford, Küttel Christine, Bhavani Mohan Preethi L., Nicolini Valeria, Birk Martina Carola, Ongaro Amandine, Prince Christophe, Gianotti Reto, Dugan Gregory, Whitlow Christopher T., Solingapuram Sai Kiran Kumar, Caudell David L., Burgos-Rodriguez Armando G., Cline J. Mark, Hettich Michael, Ceppi Maurizio, Giusti Anna Maria, Crameri Flavio, Driessen Wouter, Morcos Peter N., Freimoser-Grundschober Anne, Levitsky Victor, Amann Maria, Grau-Richards Sandra, von Hirschheydt Thomas, Tournaviti Stella, Mølhøj Michael, Fauti Tanja, Heinzelmann-Schwarz Viola, Teichgräber Volker, Colombetti Sara, Bacac Marina, Zippelius Alfred, Klein Christian, Umaña Pablo. Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. Science Translational Medicine. 2019;11(496):eaav5989. doi: 10.1126/scitranslmed.aav5989.
    1. Liu L, et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin. Cancer Res. 2015;21:1639–1651. doi: 10.1158/1078-0432.CCR-14-2339.
    1. MD H, et al. Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. Ann. Oncol. 2019;30:1134–1142. doi: 10.1093/annonc/mdz113.
    1. Eng C, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019;20:849–861. doi: 10.1016/S1470-2045(19)30027-0.
    1. Callahan MK, et al. Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) + tremelimumab (TRE) in patients with advanced solid tumors. J. Clin. Oncol. 2017;35:3069–3069. doi: 10.1200/JCO.2017.35.15_suppl.3069.
    1. Droeser RA, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur. J. Cancer. 2013;49:2233–2242. doi: 10.1016/j.ejca.2013.02.015.
    1. Mlecnik B, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J. Clin. Oncol. 2011;29:610–618. doi: 10.1200/JCO.2010.30.5425.
    1. Yu H, et al. Correlation of PD-L1 expression with tumor mutation burden and gene signatures for prognosis in early-stage squamous cell lung carcinoma. J. Thorac. Oncol. 2019;14:25–36. doi: 10.1016/j.jtho.2018.09.006.
    1. Yarchoan, M. et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight4, 10.1172/jci.insight.126908 (2019).
    1. Mehnert JM, et al. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J. Clin. Invest. 2016;126:2334–2340. doi: 10.1172/JCI84940.
    1. Gong J, Wang C, Lee PP, Chu P, Fakih M. Response to PD-1 blockade in microsatellite stable metastatic colorectal cancer harboring a POLE mutation. J. Natl Compr. Canc Netw. 2017;15:142–147. doi: 10.6004/jnccn.2017.0016.
    1. Domingo E, et al. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. Lancet Gastroenterol. Hepatol. 2016;1:207–216. doi: 10.1016/S2468-1253(16)30014-0.
    1. Ngeow J, Eng C. Mismatch repair deficiency in colorectal cancers: is somatic genomic testing the grab-bag for all answers? J. Clin. Oncol. 2016;34:2085–2087. doi: 10.1200/JCO.2016.66.7766.
    1. Pages F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391:2128–2139. doi: 10.1016/S0140-6736(18)30789-X.
    1. Mlecnik Bernhard, Van den Eynde Marc, Bindea Gabriela, Church Sarah E, Vasaturo Angela, Fredriksen Tessa, Lafontaine Lucie, Haicheur Nacilla, Marliot Florence, Debetancourt Daphné, Pairet Géraldine, Jouret-Mourin Anne, Gigot Jean-Francois, Hubert Catherine, Danse Etienne, Dragean Cristina, Carrasco Javier, Humblet Yves, Valge-Archer Viia, Berger Anne, Pagès Franck, Machiels Jean-Pascal, Galon Jérôme. Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival. JNCI: Journal of the National Cancer Institute. 2017;110(1):97–108. doi: 10.1093/jnci/djx123.
    1. Angell Helen K., Bruni Daniela, Barrett J. Carl, Herbst Ronald, Galon Jérôme. The Immunoscore: Colon Cancer and Beyond. Clinical Cancer Research. 2019;26(2):332–339. doi: 10.1158/1078-0432.CCR-18-1851.
    1. Zaretsky JM, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 2016;375:819–829. doi: 10.1056/NEJMoa1604958.
    1. Koelzer VH, Baker K, Kassahn D, Baumhoer D, Zlobec I. Prognostic impact of beta-2-microglobulin expression in colorectal cancers stratified by mismatch repair status. J. Clin. Pathol. 2012;65:996–1002. doi: 10.1136/jclinpath-2012-200742.
    1. Gray R, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–2029. doi: 10.1016/S0140-6736(07)61058-7.
    1. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet. 1995;345:939–944. doi: 10.1016/S0140-6736(95)90696-7.
    1. Smith RE, Colangelo L, Wieand HS, Begovic M, Wolmark N. Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. J. Natl Cancer Inst. 2004;96:1128–1132. doi: 10.1093/jnci/djh220.
    1. Taieb J, Andre T, Auclin E. Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives. Cancer Treat. Rev. 2019;75:1–11. doi: 10.1016/j.ctrv.2019.02.002.
    1. Sargent DJ, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol. 2010;28:3219–3226. doi: 10.1200/JCO.2009.27.1825.
    1. Schmoll HJ, et al. Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. J. Clin. Oncol. 2015;33:3733–3740. doi: 10.1200/JCO.2015.60.9107.
    1. Andre T, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J. Clin. Oncol. 2015;33:4176–4187. doi: 10.1200/JCO.2015.63.4238.
    1. Allegra CJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J. Clin. Oncol. 2011;29:11–16. doi: 10.1200/JCO.2010.30.0855.
    1. de Gramont A, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012;13:1225–1233. doi: 10.1016/S1470-2045(12)70509-0.
    1. Kerr RS, et al. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet Oncol. 2016;17:1543–1557. doi: 10.1016/S1470-2045(16)30172-3.
    1. Huang J, et al. Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin. Colorectal Cancer. 2014;13:100–109. doi: 10.1016/j.clcc.2013.12.002.
    1. Alberts SR, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012;307:1383–1393. doi: 10.1001/jama.2012.7265.
    1. Taieb J, et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:862–873. doi: 10.1016/S1470-2045(14)70227-X.
    1. Fields AL, et al. Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. J. Clin. Oncol. 2009;27:1941–1947. doi: 10.1200/JCO.2008.18.5710.
    1. Punt CJ, et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet. 2002;360:671–677. doi: 10.1016/S0140-6736(02)09836-7.
    1. Sinicrope FA, et al. Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance A021502) J. Clin. Oncol. 2017;35:TPS3630–TPS3630. doi: 10.1200/JCO.2017.35.15_suppl.TPS3630.
    1. Lau D, et al. POLEM: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer—a phase III randomized study. J. Clin. Oncol. 2019;37:TPS3615–TPS3615. doi: 10.1200/JCO.2019.37.15_suppl.TPS3615.
    1. Qin Q, Wang L. Neoadjuvant therapy and subsequent treatment in rectal cancer: balance between oncological and functional outcomes. J. Anus Rectum Colon. 2018;2:47–58. doi: 10.23922/jarc.2017-049.
    1. van Gijn W, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575–582. doi: 10.1016/S1470-2045(11)70097-3.
    1. Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 2004;351:1731–1740. doi: 10.1056/NEJMoa040694.
    1. Collette L, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J. Clin. Oncol. 2007;25:4379–4386. doi: 10.1200/JCO.2007.11.9685.
    1. Zhong X, et al. The efficacy of adding targeted agents to neoadjuvant therapy for locally advanced rectal cancer patients: a meta-analysis. Cancer Med. 2018;7:565–582. doi: 10.1002/cam4.1298.
    1. Forster Tobias, Huettner Felix J., Springfeld Christoph, Loehr Matthias, Kalkum Eva, Hackbusch Matthes, Hackert Thilo, Diener Markus K., Probst Pascal. Cetuximab in Pancreatic Cancer Therapy: A Systematic Review and Meta-Analysis. Oncology. 2019;98(1):53–60. doi: 10.1159/000502844.
    1. Kaneko M, et al. Neoadjuvant imatinib therapy in rectal gastrointestinal stromal tumors. Surg. Today. 2019;49:460–466. doi: 10.1007/s00595-018-1737-5.
    1. Ruhstaller T, et al. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08) Ann. Oncol. 2018;29:1386–1393. doi: 10.1093/annonc/mdy105.
    1. Brenner B, et al. The addition of cetuximab to preoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma is associated with high rate of long term survival: mature results from a prospective phase Ib/II trial. Radiother. Oncol. 2019;134:74–80. doi: 10.1016/j.radonc.2019.01.013.
    1. Folprecht G, et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study) Ann. Oncol. 2014;25:1018–1025. doi: 10.1093/annonc/mdu088.
    1. Ye LC, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J. Clin. Oncol. 2013;31:1931–1938. doi: 10.1200/JCO.2012.44.8308.
    1. Carrato A, et al. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: a randomised, phase II trial (PLANET-TTD) Eur. J. Cancer. 2017;81:191–202. doi: 10.1016/j.ejca.2017.04.024.
    1. Primrose J, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol. 2014;15:601–611. doi: 10.1016/S1470-2045(14)70105-6.
    1. Bisschop C, et al. Short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical treatment in primary stage IV rectal cancer: long-term results of a phase II study. Ann. Surg. Oncol. 2017;24:2632–2638. doi: 10.1245/s10434-017-5897-0.
    1. Chen HH, et al. Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial. Asia Pac. J. Clin. Oncol. 2018;14:61–68. doi: 10.1111/ajco.12692.
    1. Pietrantonio F, et al. Perioperative bevacizumab-based triplet chemotherapy in patients with potentially resectable colorectal cancer liver metastases. Clin. Colorectal Cancer. 2019;18:34–43.e36. doi: 10.1016/j.clcc.2018.11.004.
    1. Yasuno M, et al. mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival. Int. J. Clin. Oncol. 2019;24:516–525. doi: 10.1007/s10147-018-01393-8.
    1. Hasegawa S, et al. A multicenter phase 2 study on the feasibility and efficacy of neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer. Ann. Surg. Oncol. 2017;24:3587–3595. doi: 10.1245/s10434-017-5967-3.
    1. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat. Rev. Microbiol. 2014;12:661–672. doi: 10.1038/nrmicro3344.
    1. Litvak Yael, Byndloss Mariana X., Bäumler Andreas J. Colonocyte metabolism shapes the gut microbiota. Science. 2018;362(6418):eaat9076. doi: 10.1126/science.aat9076.
    1. Tilg H, Adolph TE, Gerner RR, Moschen AR. The intestinal microbiota in colorectal cancer. Cancer Cell. 2018;33:954–964. doi: 10.1016/j.ccell.2018.03.004.
    1. Ma W, et al. Gut microbiota shapes the efficiency of cancer therapy. Front Microbiol. 2019;10:1050. doi: 10.3389/fmicb.2019.01050.
    1. Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat. Rev. Gastroenterol. Hepatol. 2019;16:690–704. doi: 10.1038/s41575-019-0209-8.
    1. Xie YH, et al. Fecal Clostridium symbiosum for noninvasive detection of early and advanced colorectal cancer: test and validation studies. EBioMedicine. 2017;25:32–40. doi: 10.1016/j.ebiom.2017.10.005.
    1. Garcia-Gonzalez AP, et al. Bacterial metabolism affects the C. elegans response to cancer chemotherapeutics. Cell. 2017;169:431–441.e438. doi: 10.1016/j.cell.2017.03.046.
    1. Daillere R, et al. Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity. 2016;45:931–943. doi: 10.1016/j.immuni.2016.09.009.
    1. Alexander JL, et al. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat. Rev. Gastroenterol. Hepatol. 2017;14:356–365. doi: 10.1038/nrgastro.2017.20.
    1. Yu T, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170:548–563.e516. doi: 10.1016/j.cell.2017.07.008.
    1. Wallace BD, et al. Structure and inhibition of microbiome beta-glucuronidases essential to the alleviation of cancer drug toxicity. Chem. Biol. 2015;22:1238–1249. doi: 10.1016/j.chembiol.2015.08.005.
    1. Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat. Rev. Gastroenterol. Hepatol. 2018;15:111–128. doi: 10.1038/nrgastro.2017.119.
    1. Dossa AY, et al. Bile acids regulate intestinal cell proliferation by modulating EGFR and FXR signaling. Am. J. Physiol. Gastrointest. Liver Physiol. 2016;310:G81–G92. doi: 10.1152/ajpgi.00065.2015.
    1. Schirbel A, et al. Pro-angiogenic activity of TLRs and NLRs: a novel link between gut microbiota and intestinal angiogenesis. Gastroenterology. 2013;144:613–623.e619. doi: 10.1053/j.gastro.2012.11.005.
    1. Suh, S. H. et al. Gut microbiota regulates lacteal integrity by inducing VEGF-C in intestinal villus macrophages. EMBO Rep.20, 10.15252/embr.201846927 (2019).
    1. Chen X, et al. Probiotic yeast inhibits VEGFR signaling and angiogenesis in intestinal inflammation. PLoS ONE. 2013;8:e64227. doi: 10.1371/journal.pone.0064227.
    1. Ding L, et al. Lactobacillus rhamnosus GG ameliorates liver injury and hypoxic hepatitis in rat model of CLP-induced sepsis. Dig. Dis. Sci. 2019;64:2867–2877. doi: 10.1007/s10620-019-05628-0.
    1. Lu L, et al. Association of antibiotic exposure with the mortality in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy: a hospital-based retrospective cohort study. PLoS ONE. 2019;14:e0221964. doi: 10.1371/journal.pone.0221964.
    1. Hahn AW, et al. Targeting Bacteroides in stool microbiome and response to treatment with first-line VEGF tyrosine kinase inhibitors in metastatic renal-cell carcinoma. Clin. Genitourin. Cancer. 2018;16:365–368. doi: 10.1016/j.clgc.2018.05.001.
    1. Lalani, A. A. et al. Effect of antibiotic use on outcomes with systemic therapies in metastatic renal cell carcinoma. Eur. Urol. Oncol. 10.1016/j.euo.2019.09.001 (2019).
    1. Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science. 2018;359:1366–1370. doi: 10.1126/science.aar6918.
    1. Fessler J, Matson V, Gajewski TF. Exploring the emerging role of the microbiome in cancer immunotherapy. J. Immunother. Cancer. 2019;7:108. doi: 10.1186/s40425-019-0574-4.
    1. Elkrief A, Derosa L, Zitvogel L, Kroemer G, Routy B. The intimate relationship between gut microbiota and cancer immunotherapy. Gut Microbes. 2019;10:424–428. doi: 10.1080/19490976.2018.1527167.
    1. Sivan A, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350:1084–1089. doi: 10.1126/science.aac4255.
    1. Anderson R, Theron AJ, Rapoport BL. Immunopathogenesis of immune checkpoint inhibitor-related adverse events: roles of the intestinal microbiome and Th17 cells. Front. Immunol. 2019;10:2254. doi: 10.3389/fimmu.2019.02254.
    1. Vetizou M, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350:1079–1084. doi: 10.1126/science.aad1329.
    1. Chaput N, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann. Oncol. 2017;28:1368–1379. doi: 10.1093/annonc/mdx108.
    1. Derosa L, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann. Oncol. 2018;29:1437–1444. doi: 10.1093/annonc/mdy103.
    1. Elkrief A, et al. Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. Oncoimmunology. 2019;8:e1568812. doi: 10.1080/2162402X.2019.1568812.
    1. Gopalakrishnan V, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97–103. doi: 10.1126/science.aan4236.
    1. Matson V, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359:104–108. doi: 10.1126/science.aao3290.
    1. Tanoue T, et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature. 2019;565:600–605. doi: 10.1038/s41586-019-0878-z.
    1. Zhao S, et al. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer. Lung Cancer. 2019;130:10–17. doi: 10.1016/j.lungcan.2019.01.017.
    1. Pinato David J., Howlett Sarah, Ottaviani Diego, Urus Heather, Patel Aisha, Mineo Takashi, Brock Cathryn, Power Danielle, Hatcher Olivia, Falconer Alison, Ingle Manasi, Brown Anna, Gujral Dorothy, Partridge Sarah, Sarwar Naveed, Gonzalez Michael, Bendle Maggie, Lewanski Conrad, Newsom-Davis Thomas, Allara Elias, Bower Mark. Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer. JAMA Oncology. 2019;5(12):1774. doi: 10.1001/jamaoncol.2019.2785.
    1. Routy B, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–97. doi: 10.1126/science.aan3706.
    1. Ansaldo E, et al. Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis. Science. 2019;364:1179–1184. doi: 10.1126/science.aaw7479.
    1. Strosberg JR, et al. A phase II study of RO4929097 in metastatic colorectal cancer. Eur. J. Cancer. 2012;48:997–1003. doi: 10.1016/j.ejca.2012.02.056.
    1. Berlin J, et al. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin. Cancer Res. 2013;19:258–267. doi: 10.1158/1078-0432.CCR-12-1800.
    1. Villalba M, Evans SR, Vidal-Vanaclocha F, Calvo A. Role of TGF-beta in metastatic colon cancer: it is finally time for targeted therapy. Cell Tissue Res. 2017;370:29–39. doi: 10.1007/s00441-017-2633-9.
    1. Ghosh N, Hossain U, Mandal A, Sil PC. The Wnt signaling pathway: a potential therapeutic target against cancer. Ann. NY Acad. Sci. 2019;1443:54–74. doi: 10.1111/nyas.14027.
    1. Guinney J, et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 2015;21:1350–1356. doi: 10.1038/nm.3967.
    1. Lenz HJ, et al. Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405 (Alliance) J. Clin. Oncol. 2019;37:1876–1885. doi: 10.1200/JCO.18.02258.
    1. Dienstmann R, et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat. Rev. Cancer. 2017;17:79–92. doi: 10.1038/nrc.2016.126.
    1. Mooi JK, et al. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial. Ann. Oncol. 2018;29:2240–2246. doi: 10.1093/annonc/mdy410.
    1. Fontana E, Eason K, Cervantes A, Salazar R, Sadanandam A. Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials. Ann. Oncol. 2019;30:520–527. doi: 10.1093/annonc/mdz052.
    1. Roelands Jessica, Kuppen Peter, Vermeulen Louis, Maccalli Cristina, Decock Julie, Wang Ena, Marincola Francesco, Bedognetti Davide, Hendrickx Wouter. Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications. International Journal of Molecular Sciences. 2017;18(10):2229. doi: 10.3390/ijms18102229.
    1. Peeters M, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol. 2010;28:4706–4713. doi: 10.1200/JCO.2009.27.6055.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅